Physician profile
Keith R Hoffmann
NPI 1497853121
$5,784.60
in general payments reported to CMS, 2019-2025
35 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.89 · 2020: $218 · 2021: $584 · 2022: $415 · 2023: $1,213 · 2024: $1,475 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,551.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $919.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $622.31 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $590.05 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $444.42 | 2019-2025 | |
| Amgen INC. | $403.95 | 2020-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.25 | 2021-2025 | Jardiance, Spiriva Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $358.21 | 2024-2025 | Caplyta |
| Abbvie INC. | $357.69 | 2021-2025 | |
| Glaxosmithkline, LLC. | $314.16 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $258.31 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $169.36 | 2023-2024 | Veozah |
| Axsome Therapeutics, INC. | $137.92 | 2024-2025 | Auvelity |
| Amarin Pharma, INC. | $83.45 | 2020-2021 | |
| Exact Sciences Corporation | $83.35 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $79.86 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $55.13 | 2022-2023 | |
| Dexcom, INC. | $54.06 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $48.74 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $48.69 | 2023 | Aplenzin |
| Kowa Pharmaceuticals America, INC. | $46.85 | 2021-2022 | |
| Viatris Specialty LLC | $36.95 | 2025 | Yupelri |
| Alnylam Pharmaceuticals INC. | $31.47 | 2020-2021 | |
| Qol Medical, LLC | $28.16 | 2021 | |
| Abiomed | $23.49 | 2024 | |
| Allergan, INC. | $21.24 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.70 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.58 | 2023 | Rexulti |
| Eisai INC. | $18.72 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.06 | 2023 | Xifaxan |
| Actelion Pharmaceuticals US, INC. | $16.52 | 2025 | Uptravi, Opsumit |
| Ibsa Pharma INC. | $16.37 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.80 | 2021 | |
| Bardy Diagnostics, INC. | $15.14 | 2022 | |
| Seqirus USA INC | $13.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.95 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.